DEVELOPING
Importance
68
Trust
71
Urgency
65
COMMERCIAL
The Oral GLP-1 Tracker: Foundayo still lagging Wegovy pill in week 3 as insurance boost nears - Fierce Pharma
Foundayo, an oral weight-loss pill, is selling slower than Novo Nordisk's Wegovy pill in its first three weeks on the market. Insurance coverage for Foundayo is expected to improve soon, which could help it catch up in sales.
Analysis
Lilly's new weight-loss pill Foundayo is off to a slow start. Novo's Wegovy pill is selling better. Better insurance coverage could help Foundayo catch up.
- Foundayo is trailing Novo's Wegovy pill in its first three weeks on sale
- Insurance coverage for Foundayo is expected to improve soon
Novo Nordisk News1mo
Read